SEC Comment Letter for Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Sep 11, 2018
Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: Sept. 11, 2018 · CIK: 0001533040 · Accession: 0000000000-18-028212
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227173
Letter
September 10, 2018 Geert Cauwenbergh President and Chief Executive Officer RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough, MA 01752 Re:RXi Pharmaceuticals Corporation Registration Statement on Form S-1 Filed August 31, 2018 File No. 333-227173 Dear Dr. Cauwenbergh: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Ryan Murr
Show Raw Text
September 10, 2018
Geert Cauwenbergh
President and Chief Executive Officer
RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough, MA 01752
Re:RXi Pharmaceuticals Corporation
Registration Statement on Form S-1
Filed August 31, 2018
File No. 333-227173
Dear Dr. Cauwenbergh:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Ryan Murr